Title | Possible mechanisms of cancer prevention by nicotinamide. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Buqué A, Bloy N, Kroemer G, Galluzzi L |
Journal | Br J Pharmacol |
Volume | 178 |
Issue | 10 |
Pagination | 2034-2040 |
Date Published | 2021 May |
ISSN | 1476-5381 |
Keywords | Dietary Supplements, Humans, Neoplasms, Niacinamide, Randomized Controlled Trials as Topic |
Abstract | Nicotinamide (NAM) is a precursor of vitamin B commonly sold over the counter as a nutritional supplement with anti-aging properties. Accumulating preclinical evidence indicates that NAM also mediates oncopreventive effects against a variety of neoplasms. Supporting the translational relevance of dietary NAM supplementation, results from a Phase 3 randomized clinical trial have demonstrated that oral NAM was safe and efficiently reduced the incidence of new non-melanoma skin cancers and actinic keratosis amongst high-risk individuals. However, the molecular and cellular mechanisms that underlie this ability of NAM to delay carcinogenesis remain to be clarified, as discussed in this short review. LINKED ARTICLES: This article is part of a themed issue on Cellular metabolism and diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.10/issuetoc. |
DOI | 10.1111/bph.15096 |
Alternate Journal | Br J Pharmacol |
PubMed ID | 32383227 |
Grant List | BC180476P1 / / Breast Cancer Research Program (BRCP) / |